← All trials
NCT05685277
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 28, 2022
- Primary completion
- Feb 22, 2023
- Completion date
- Jul 31, 2023
- First posted
- Jan 17, 2023
- Last posted
- Aug 4, 2023
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmtechnology LLCLead sponsor
- Ligand Research, LLCCollaborator
- Ligand Research, LLCOverall official - principal investigator
- Ligand Research, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.